SignalCorporate
Astellas Pharma ADR GAAP EPS of v134.47, revenue of ¥1270.86B; updates FY2027 outlook
Astellas reported EPS of v134.47 and ¥1270.86B revenue while updating FY2027 outlook.
Context
What happened: Astellas Pharma ADR reported first half GAAP EPS of ¥134.47 and revenue of ¥1,270.86B, and updated its FY2027 outlook.
Key numbers: 1H GAAP EPS ¥134.47. Revenue ¥1,270.86B, up 23.4% Y/Y.
Why it matters: The results came alongside an updated FY2027 outlook. Related coverage notes new drug-pricing accords involving Astellas among other biotech drugmakers.
Coverage: 3 outlets in 24h
What changed
Astellas Pharma ADR reported first half GAAP EPS of ¥134.47 and revenue of ¥1,270.86B, and updated its FY2027 outlook.
Why it matters
The results came alongside an updated FY2027 outlook. Related coverage notes new drug-pricing accords involving Astellas among other biotech drugmakers.